90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24043955 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Pasqua Letizia Pesole und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Gastroenterology-IRCCS, "Saverio de Bellis", 70013 Castellana Grotte, Italy. Hauptthemen laut MEDLINE: Biological Products, Colitis, Ulcerative, Crohn Disease, Infliximab. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.
Abstract (Originalsprache)
Inflammatory bowel diseases (IBD), comprising Crohn’s disease (CD) and Ulcerative Colitis (UC), are multifactorial disorders characterized by a chronic inflammatory status with the secretion of cytokines and immune mediators. Biologic drugs targeting pro-inflammatory cytokines, such as infliximab, are broadly used in the treatment of IBD patients, but some patients lose responsiveness after an initial success. The research into new biomarkers is crucial for advancing personalized therapies and monitoring the response to biologics. The aim of this single center, observational study is to analyze the relationship between serum levels of 90K/Mac-2 BP and the response to infliximab, in a cohort of 48 IBD patients (30 CD and 18 UC), enrolled from February 2017 to December 2018. In our IBD cohort, high 90K serum levels were found at baseline in patients who then developed anti-infliximab antibodies at the fifth infusion (22 weeks after the first), becoming non-responders (9.76 ± 4.65 µg/mL compared to 6.53 ± 3.29 µg/mL in responder patients, p = 0.005). This difference was significant in the total cohort and in CD, but not significant in UC. We then analyzed the relationship between serum levels of 90K, C-reactive protein (CRP), and Fecal calprotectin. A significant positive correlation was found at baseline between 90K and CRP, the most common serum inflammation marker (R = 0.42, p = 0.0032). We concluded that circulating 90K could be considered a new non-invasive biomarker for monitoring the response to infliximab. Furthermore, 90K serum level determination, before the first infliximab infusion, in association with other inflammatory markers such as CRP, could assist in the choice of biologics for the treatment of IBD patients, thereby obviating the need for a drug switch due to loss of response, and so improving clinical practice and patient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Institute of Gastroenterology-IRCCS, "Saverio de Bellis", 70013 Castellana Grotte, Italy.
ORCID-Profile: Pasqua Letizia Pesole, Marina Liso, Rossella Donghia, Palma Aurelia Iacovazzi
Förderung
- Italian Ministry of Health
Zitieren
APA
Pesole, P. L., Liso, M., Donghia, R., Guerra, V., Lippolis, A., Mastronardi, M., & Iacovazzi, P. A. (2023). 90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043955
Vancouver
Pesole PL, Liso M, Donghia R, Guerra V, Lippolis A, Mastronardi M, et al. 90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043955
BibTeX
@article{Pesole2023,
author = {Pesole, Pasqua Letizia and Liso, Marina and Donghia, Rossella and Guerra, Vito and Lippolis, Antonio and Mastronardi, Mauro and Iacovazzi, Palma Aurelia},
title = {90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24043955}
}
EUVIMED